Retatrutide is an investigational triple incretin receptor agonist that simultaneously activates GLP-1, GIP, and glucagon receptors, producing appetite suppression, enhanced insulin secretion, and increased energy expenditure, though long-term safety and cardiovascular outcome data are not yet available
J., Basagoiti-Carreo, B., Sanz-Velasco, A., Serrano-Moreno, C
Choosing retatrutide alone gives you everything semaglutide would contribute inside one titrated molecule, without the redundant second injection
This class of medications is also associated with promoting weight loss and a low risk of hypoglycemia, and some have been shown to be associated with a significant reduction of major cardiovascular events
Henry Meds and Eden round out the list with strong prepay discounts and coaching, respectively
However, the appetite-suppressing effects of Ozempic may take a few days to become noticeable, and the degree of change can differ from person to person